We, at White Cloud Electronic Cigarettes, believe that e-cigs have a vitally important role to play in reducing the harm caused to smokers by conventional tobacco products. There are also many in the area of Public Health that share that belief.
Here are a few whose opinions are of a similar view, but also base their opinions on available facts and scientific data, rather than speculation and scare-mongering:
Jeff is a senior fellow at the National Center for Public Policy Research in Washington, D.C., USA, and heads its risk analysis division. Stier is a frequent guest on CNBC and has addressed health policy on CNN, the Fox News Channel and MSNBC as well as network newscasts. He appears in more than 100 radio shows a year—on NPR and other nationally syndicated radio shows—as well as major shows in cities such as Boston, Philadelphia and Dallas, plus regional broadcasts. Stier’s op-eds have been published in outlets including The Los Angeles Times, The New York Post and Newsday. Stier has also testified at the federal, state and local levels about e-cigarette regulation.
Carl V Phillips
Carl is a consultant and freelance researcher in epidemiology and economics, and he is the scientific director for The Consumer Advocates for Smoke-free Alternatives Association. He has worked in tobacco harm-reduction (THR) research, education and advocacy, and is one of the few who have been in the field for more than a decade, starting during his previous career as a professor of public health. His current work focuses on chronicling and analyzing the experiences of consumers who have employed THR and on population modeling of product adoption.
David is Adjunct Professor, Faculty of Law, University of Ottawa
He has spearheaded the development of world-leading tobacco control initiatives in Canada since the 1980s, first as counsel to the Non-Smokers Rights Association and then as an independent consultant. He played a key role in Canadian efforts on, among other things, tobacco taxation, advertising restrictions, package warnings, environmental tobacco smoke, smoking cessation, litigation and product regulation David received his undergraduate degree from the University of Western Ontario in 1978, a law degree from the University of Toronto in 1981, and was called to the bar of the Law Society of Upper Canada in 1983. He has applied that training to public health policy, specializing in tobacco issues, and focusing on how legal measures can greatly impact population health.
Scott has spent 40-plus years working on issues related to tobacco and public health. He served as the American Heart Association’s vice president and legislative counsel, as a steering committee member and as chairman of the Coalition on Smoking or Health. Ballin was instrumental in advocating the regulation of tobacco products by the U.S. Food and Drug Administration. He also worked for the Alliance for Health Economic and Agriculture Development, an organization formed to help enact the recommendations in Tobacco at a Crossroads. He continues work on tobacco harm-reduction issues and serves as an adviser to the University of Virginia on tobacco, nicotine and alternative products/harm-reduction dialogues.
Clive is director of Counterfactual, a public interest consulting and advocacy group. Previously, he was a senior civil servant at the Department of Energy and Climate Change and director general for sustainable futures with the Welsh government. In 1997, he became the executive director of Action on Smoking and Health, pursuing a strategy to reduce harm and inequalities arising from tobacco use. In 2003, he became a senior adviser in the prime minister’s strategy unit. Bates moved to the Environment Agency in 2005. In 2009, he established the U.N. Environment Program in Sudan, focusing on improving natural resource management.
Dr. Siegel is a Professor in the Department of Community Health Sciences, Boston University School of Public Health. He has 25 years of experience in the field of tobacco control. He previously spent two years working at the Office on Smoking and Health at CDC, where he conducted research on secondhand smoke and cigarette advertising. He has published nearly 70 papers related to tobacco. He testified in the landmark Engle lawsuit against the tobacco companies, which resulted in an unprecedented $145 billion verdict against the industry. He teaches social and behavioral sciences, mass communication and public health, and public health advocacy in the Masters of Public Health program.
Professor Rodu has been appointed the first holder of the Endowed Chair in Tobacco Harm Reduction Research at the University of Louisville’s James Graham Brown Cancer Center. His research focuses on the substitution of safer tobacco products by smokers who are unable or unwilling to quit smoking with conventional cessation methods because of their addiction to nicotine. His research in comparative epidemiology established the scientific foundation for harm reduction and he continues to study clinical and social interventions aimed at harm reduction.
Tobacco harm reduction has been popular among Swedish men, who have the lowest smoking rate and highest smokeless tobacco usage rate in Europe. In a study published in the Journal of Internal Medicine, Rodu found that smokeless tobacco products were primarily responsible for a decline in smoking among Swedish men from 23 percent in 1986 to 14 percent in 1999.
Rodu has published a book summarizing his research, as well as several book chapters and more than 150 articles and abstracts in peer-reviewed journals. He has been principal investigator for numerous clinical trials and extramurally-funded studies. Prior to joining U of L in 2005, Rodu served on the faculty of the University of Alabama at Birmingham, where most of his research was conducted.
Rodu earned his D.D.S. at the Ohio State University, completed a residency in oral pathology at Emory University in Atlanta, and was awarded NCI and ACS fellowships at UAB.